Vitae Pharmaceuticals Inc. (VTAE) Downgraded by Stifel Nicolaus
Stifel Nicolaus lowered shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) from a buy rating to a hold rating in a report released on Wednesday. The brokerage currently has $21.00 price target on the stock.
Several other analysts have also commented on the stock. Wells Fargo & Co. lowered shares of Vitae Pharmaceuticals from an outperform rating to a market perform rating in a research report on Sunday, September 11th. JMP Securities lowered shares of Vitae Pharmaceuticals from an outperform rating to a market perform rating in a research report on Thursday, August 4th. Wedbush reiterated an outperform rating and issued a $23.00 target price on shares of Vitae Pharmaceuticals in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research lowered shares of Vitae Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 13th. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Vitae Pharmaceuticals has an average rating of Hold and an average price target of $19.05.
Shares of Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 20.95 on Wednesday. The stock’s market capitalization is $604.22 million. The company has a 50-day moving average of $8.53 and a 200-day moving average of $8.41. Vitae Pharmaceuticals has a 52-week low of $4.08 and a 52-week high of $20.95.
Vitae Pharmaceuticals (NASDAQ:VTAE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative net margin of 13,954.35% and a negative return on equity of 65.51%. The company’s revenue for the quarter was down 98.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.45) EPS. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($1.64) EPS for the current year.
In related news, CEO Jeffrey S. Hatfield sold 50,000 shares of the business’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the transaction, the chief executive officer now directly owns 244,996 shares in the company, valued at $5,098,366.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,025,000 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $20.85, for a total transaction of $21,371,250.00. The disclosure for this sale can be found here. Corporate insiders own 14.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the company. BlackRock Advisors LLC raised its position in Vitae Pharmaceuticals by 73.8% in the second quarter. BlackRock Advisors LLC now owns 10,078 shares of the company’s stock worth $109,000 after buying an additional 4,280 shares during the last quarter. Trexquant Investment LP acquired a new position in Vitae Pharmaceuticals during the second quarter worth $119,000. Spark Investment Management LLC raised its position in Vitae Pharmaceuticals by 10.8% in the first quarter. Spark Investment Management LLC now owns 18,400 shares of the company’s stock worth $121,000 after buying an additional 1,800 shares during the last quarter. TFS Capital LLC acquired a new position in Vitae Pharmaceuticals during the second quarter worth $126,000. Finally, Alliancebernstein L.P. acquired a new position in Vitae Pharmaceuticals during the second quarter worth $140,000. Hedge funds and other institutional investors own 72.93% of the company’s stock.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.
Receive News & Ratings for Vitae Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.